Revelation Biosciences, Inc.
REVB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.02 | 0.02 |
| FCF Yield | -42.31% | -106.27% | -36.46% | -48.64% |
| EV / EBITDA | 4.71 | 1.37 | -1.90 | -0.67 |
| Quality | ||||
| ROIC | -17.66% | -64.33% | -72.72% | -37.25% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.83 | 0.79 | 1.36 | 2.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 17.21% | 31.32% | 25.08% | 59.78% |
| Safety | ||||
| Net Debt / EBITDA | 6.69 | 2.11 | 1.77 | 3.72 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |